{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:01:22Z","timestamp":1792051282797,"version":"4.4.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,21]]},"DOI":"10.1093\/ibd\/izy272","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T16:24:33Z","timestamp":1535127873000},"page":"580-586","source":"Crossref","is-referenced-by-count":54,"title":["Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"25","author":[{"given":"Badr","family":"Al-Bawardy","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Piovezani","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice V","family":"Willrich","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyoung","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satimai","family":"Aniwan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"},{"name":"Division of Gastroenterology, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayla A","family":"Schoenoff","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Bruining","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A","family":"Papadakis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Raffals","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Tremaine","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"key":"key\n\t\t\t\t2019022112504358600_CIT0001","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/MIB.0000000000000816","article-title":"Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis","volume":"22","author":"Reinink","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0002","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0003","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: a systematic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0004","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/MEG.0b013e32835414b2","article-title":"Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease","volume":"24","author":"Casellas","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0007","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/MIB.0b013e3182813242","article-title":"Serum adalimumab concentration and clinical remission in patients with Crohn\u2019s disease","volume":"19","author":"Chiu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0008","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ecco-jcc\/jjw014","article-title":"Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn\u2019s disease","volume":"10","author":"Zittan","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0009","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000000689","article-title":"Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Yarur","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0011","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0012","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0013","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0014","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0015","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0016","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0017","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0018","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0019","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/ecco-jcc\/jjx180.645","article-title":"P518 Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease","volume":"12","author":"Chao","year":"2018","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0020","volume-title":"A Language and Environment for Statistical Computing","author":"Team RDC","year":"2015"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0021","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0022","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0024","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cgh.2013.10.025","article-title":"Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0027","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5414\/CPP48596","article-title":"Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity","volume":"48","author":"Xu","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0028","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MEG.0b013e32835d1f15","article-title":"Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn\u2019s disease","volume":"25","author":"Bhalme","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0029","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key\n\t\t\t\t2019022112504358600_CIT0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/3\/580\/27940889\/izy272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T21:13:11Z","timestamp":1550783591000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/25\/3\/580\/5079133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,8,24]]},"published-print":{"date-parts":[[2019,2,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy272","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,8,24]]}}}